SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the…
This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates…
TAMPA, Fla., April 24, 2024 /PRNewswire/ -- St. Joseph's Hospital today announced that it becomes the first health care facility…
Expedited checkout requires limited staff overnight, enabling nearly 24/7 accessSCOTTSDALE, Ariz.--(BUSINESS WIRE)--Quickcharge, a dining and retail technology platform for Healthcare,…
PALO ALTO, CA / ACCESSWIRE / April 24, 2024 / Bioz, Inc., a Silicon Valley AI company, has partnered with…
PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage…
Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA…
Company Announces 11th Recent System Installed in Israel, with More Expected this YearBURLINGTON, Mass. and JERUSALEM, April 17, 2024 (GLOBE…
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression…
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing…